The landscape of diabetes management is rapidly shifting, with the emergence of dual GIP and GLP-1 receptor agonists. Both Tirzepatid and Retatru tide represent key advancements; Tirzepatid already https://geraldynbj862028.smblogsites.com/43009720/tirzepatid-retatrutide-a-new-weight-management-duo